Skip to content
Screener

Metagenomi Therapeutics, Inc. MGX Q1 2026 earnings

Reported May 11, 2026 · Before market open

Revenue$1.2MMiss by $4.7M
EPS-$0.61Miss by $0.01
Revenue estimate$5.9M
EPS estimate-$0.60

Next report

Nov 10, 2026 (in 2 months)
Revenue estimate$2.6M
EPS estimate-$0.64

FAQ

When did Metagenomi Therapeutics, Inc. report Q1 2026 earnings?
Metagenomi Therapeutics, Inc. (MGX) reported Q1 2026 earnings on May 11, 2026 before market open.
What were Metagenomi Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Metagenomi Therapeutics, Inc. reported revenue of $1.2M and eps of $-0.61 for Q1 2026.
Did Metagenomi Therapeutics, Inc. beat estimates in Q1 2026?
Revenue missed the consensus estimate of $5.9M by $4.7M. EPS missed the consensus estimate of $-0.60 by $0.01.
How did Metagenomi Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 69.8% from $4.1M a year earlier and eps grew 10.3% from $-0.68.
Where can I find Metagenomi Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-216763) and the 10-Q periodic report (0001193125-26-216774) directly on SEC EDGAR. The filing index links above go to sec.gov.